Document is current
Any future updates will be listed below
-
Authors
Izadifar, Mohammad https://orcid.org/0000-0001-5542-4335
Massumi, Mohammad
Prentice, Kacey J.
Oussenko, Tatiana
Li, Biao
Elbaz, Judith
Puri, Mira
Wheeler, Michael B.
Nagy, Andras https://orcid.org/0000-0003-4311-0413
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research Foundation Grant (143231)
Canada Research Chairs (950-230422)
Medicine by Design
Banting and Best Diabetes Centre, University of Toronto
- License Information
-
More Information
Article History
Received: 10 July 2024
Accepted: 10 November 2024
First Online: 18 December 2024
Declarations
:
: Details of ethics approvals: Title of the approved project: Characterizing the reprogramming process in vivo by using pancreatic endocrine cells to compensate for the beta cell ablated pancreas. Name of the institutional approval committee: The ethics board of The Centre for Phenogenomics (TCP). Approval number: AUP#0182. Date of approval (dd-mm-yy): 08–03-2018. Authors confirm that no human participant was involved in this study; thus, ‘patient consent’ was not applicable for this study.
: All authors confirm their consent for publication.
: The authors declare that they have no competing interests.
